Prospective Isolation and Characterization of Genetically and Functionally Distinct AML Subclones

Area of Science:

• Oncology
• Proteomics
• Genomics

Background:

• Intra-tumor heterogeneity, driven by clonal evolution, poses a significant challenge in cancer therapy.
• Acute myeloid leukemia (AML) exhibits substantial heterogeneity, complicating treatment strategies.

Purpose of the Study:

• To develop a method for isolating and characterizing genetically distinct subclones within individual AML patients.
• To identify novel protein markers for stratifying AML diagnosis and treatment.

Main Methods:

• Label-free quantitative proteomics was employed on primary AML samples.
• Identification of 50 leukemia-enriched plasma membrane proteins.
• Subclone characterization using RNA sequencing, epigenetic profiling, and functional assays (in vitro and xenograft).

Main Results:

• Successfully isolated genetically distinct AML subclones using identified plasma membrane proteins.
• Demonstrated significant differences in regulatory phenotype, drug sensitivity, growth, and engraftment among subclones.
• Validated the utility of these markers for longitudinal tracking of leukemic clones in patients.

Conclusions:

• The identified plasma membrane proteins provide a robust strategy for isolating and characterizing AML subclones.
• This approach significantly enhances the potential for improved cancer diagnosis and personalized treatment stratification.
• Enables longitudinal monitoring of distinct leukemic clones in routine clinical diagnostics.